Pharma BD Deal Intelligence

Amgen Inc. / Dark Blue Therapeutics Ltd.

2026 · Acquisition/Merger · $840M · Complete

Amgen acquired Dark Blue Therapeutics Ltd., a privately held UK biotechnology company developing first-in-class small-molecule targeted protein degraders for oncology, in a transaction valued at up to USD 840M. The acquisition adds DBT 3757, an investigational degrader of the MLLT1 and MLLT3 proteins that drive certain acute myeloid leukemia and acute lymphoblastic leukemia subtypes. DBT 3757 was in IND-enabling studies at announcement.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Amgen Inc. deals